DELFI INCLUDE Study (Lung Cancer Screening)

DELFI INCLUDE Study (Lung Cancer Screening)

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to learn more about the DELFI Lung Cancer Screening Test. We want to know when it is most appropriate and beneficial for people to have this test. The test is designed to diagnose lung cancer early through blood analysis.

Who Can Participate?

Eligibility

Adults ages 50-80 who:
  • Are current or former smokers
  • Have not had a CT scan or any other test to detect lung cancer in the last 15 months
  • Have a smoking history of at least 20 "pack years" (1 pack of cigarettes per day for one year = 1 pack year)
For more information about who can join this study, please contact the study team at autumn.konz@duke.edu.

What is Involved?

Description

Duke patients will be invited to take part in this research study because your primary care provider has requested that you receive a DELFI Lung Cancer Screening Test. If you choose to join the study, you will have a blood draw to detect lung cancer. Following this test, you will get a random assignment (like a coin flip) to 1 of 2 groups for follow-up care:
  • One group will get standard educational materials for lung cancer screening
  • The other group will get Delfi Lung Cancer Screening Test Education with education on lung cancer screening
Your medical provider will be able to provide you with the results of this test. Depending on the results of your test, your medical provider may order additional testing.

Study Details

Full Title

Implementing Fragmentomics Into Real World Screening IntervenTions to evaluate clinical utility among individuals with elevated risk for Lung Cancer (FIRSTLUNG) L301

Principal Investigator

James
Davis

Protocol Number

PRO00113980

NCT ID

NCT06145750

Phase

N/A

Enrollment Status

Open to Enrollment
ClinicalTrials.gov